Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score

Modern Pathology

Volumn 28, Issue 9, 2015, Pages 1167-1173

  Knopfelmacher, Adriana ^a   Fox, Jana ^a   Lo, Yungtai ^a   Shapiro, Nella ^a,b   Fineberg, Susan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Eastchester Center for Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE M1; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST NECROSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CELL COUNT; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMEDO; CONTROLLED STUDY; DISEASE ASSESSMENT; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; INTRADUCTAL CARCINOMA; LOW RISK PATIENT; MITOSIS; ONCOTYPE DX INTRADUCTAL CARCINOMA SCORE; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; BREAST TUMOR; GENETICS; MIDDLE AGED; MITOSIS INDEX; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84940719947     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.79     Document Type: Article

References (20)

1. Rakovitch E, Pignol JP, Chartier C et al. The management of ductal carcinoma in situ of the breast: A screened population-based analysis. Breast Cancer Res Treat 2007;101:429-438.
2. Fisher ER, Dignam J, Tan-Chiu E et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight year update of Protocol B-17. Cancer 1999;86:429-438.
3. Wapnir I, Dignam J, Fisher B et al. Long term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103: 478-488.
4. Fisher B, Digman J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16: 441-452.
5. Gradishar WJ, Anderson BO, Balassanian R et al. NCCN Clinical Practice Guidelines in Oncology: Breast cancer http://www.nccn.org/professions/physiciansgls/pdf/breast. pdf.Version1.2014.
6. Goodwin A, Parker S, Ghersi D et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast - A systemic review of the randomized trials. Breast 2009;18:143-149.
7. Hughes L, Wang M, Page D et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
8. Motwani S, Goyal S, Moran M et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: A comparison with ECOG study 5194. Cancer 2011;177:1156-1162.
9. Early Breast Cancer Trialist's Collaborative Group (EBCTCG), Correa C, McGale P et al. Overview of the randomized trials of radiotherapy in ductal carcinoma In situ. J Natl Cancer Inst Monogr 2010;41: 162-177.
10. Solin L, Gray R, Baehner F et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105:701-710.
11. Rakovitch E. Oncotype DX DCIS score predicts recurrence. Cancer Discov. 2014;5: OF3 Published online first, 23 December 2014.
12. Fang J, Wang S, Zhang S et al. Association of the glutathione s-transferase M1, T1 polymorphisms with cancer: evidence from a meta-analysis. PLOS One 2013;8:e78707.
13. Badve S, Gray R, Baehner F et al. Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. J Clin Oncol 2012;30, (suppl;abstr 1005).
14. Elston C, Ellis I. Pathologic prognostic factors in breast cancer: the value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
15. Lester S, Bose S, Chen Y et al. Protocol for the examination of specimens from patients with DCIS of the breast http://www.cap.org/cancerprotocols Dec 2013.
16. Lari S, Kuerer N. Biologic markers in DCIS and risk of breast recurrence: A systemic review. J Cancer 2011;2: 232-261.
17. Allen M, Thomas G, Clark S et al. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of ?v?6 integrin in DCIS identifies high risk patients and predicts recurrence. Clin Cancer Res 2014;20:344-357.
18. Cowell C, Weigelt B, Sakr R et al. Progression form ductal carcinoma insitu to invasive breast cancer: revisited. Mol Oncol 2013;7:859-869.
19. Ma X, Dahiya S, Richardson E et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009;11:R7.
20. Salgado R, Denkert C, Demaria S et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TIL) in breast cancer: recommendations by an international TILs working group 2014. Ann Clin Oncol 2014;00:1-13.